Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Illinois Tysabri PML Injury Lawyer

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Risk Awareness

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment protocols, and preventive care. This legacy established a broad framework for interpreting clinical data and patient outcomes, often emphasizing the balance between therapeutic benefit and potential adverse effects. Within this context, the introduction of biologic therapies such as Tysabri represented a significant advancement in managing chronic inflammatory conditions, yet it also brought heightened awareness of associated risks, including progressive multifocal leukoencephalopathy (PML). As the focus narrows from general health education to specific clinical realities, a critical pivot emerges: the occupational exposure dimension. While PML risk is primarily discussed in patient populations receiving immunosuppressive therapy, the manufacturing, handling, and administration of such biologics introduce distinct exposure pathways for workers in pharmaceutical production, healthcare settings, and related industries. These occupational contexts require separate consideration, as routine safety protocols may not fully address the chronic, low-level contact with active pharmaceutical ingredients or contaminated materials. The transition from broad health literacy to targeted occupational concern thus demands a reassessment of risk communication, moving from population-level advisories to workplace-specific safeguards. This shift underscores the need for legal and regulatory frameworks that recognize the unique vulnerabilities of those whose daily work intersects with high-potency therapeutics.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic medication approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical trial data and post-marketing surveillance. PML is caused by reactivation of the JC virus in immunocompromised individuals. Tysabri works by blocking the migration of immune cells into the central nervous system, which can impair the brain's ability to control JC virus replication. The FDA label identifies three key risk factors for PML in Tysabri-treated patients: "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who test positive for anti-JCV antibodies have a higher risk, and the risk increases with longer treatment duration, especially beyond two years. Prior use of immunosuppressive medications further elevates the risk.

Clinical Presentation and Diagnosis of PML

Clinical presentation of PML typically includes progressive neurological deficits such as weakness, cognitive impairment, vision changes, and coordination problems. The FDA label advises healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Diagnosis is confirmed through MRI imaging and detection of JC virus DNA in cerebrospinal fluid. The prognosis is poor, with most cases leading to severe disability or death. In clinical trials, PML occurred in three patients who received Tysabri. According to the FDA label, "two cases of PML were observed in the 1869 patients with multiple sclerosis who were treated for a median of 120 weeks" and "the third case occurred after eight doses in one of the 1043 patients with Crohn's disease" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing adverse event reports from the FDA Adverse Event Reporting System (FAERS) list thousands of reports associated with Tysabri, including fatigue, multiple sclerosis relapse, headache, and gait disturbance, though PML is a specific and severe outcome (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI).

Mechanism of Tysabri-Associated PML

The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking the adhesion molecule VLA-4, Tysabri prevents lymphocytes from crossing the blood-brain barrier. This reduces immune surveillance in the central nervous system, allowing JC virus to replicate unchecked in oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The risk is compounded by the fact that JC virus is latent in many individuals, and immunosuppression from Tysabri can trigger reactivation. Given the severity of PML, the adequacy of warnings to patients and healthcare providers is a critical concern. The FDA requires Tysabri to be distributed through a restricted program called the TOUCH Prescribing Program, which mandates that patients be educated about PML risks and that prescribers follow specific monitoring protocols (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients may develop PML without adequate prior warning or understanding of their individual risk factors.

Legal Considerations for Tysabri-Related PML

For affected patients, legal considerations may arise regarding whether the manufacturer provided sufficient information about the risk of PML, especially in relation to duration of therapy and antibody status. The timeline between Tysabri exposure and PML onset varies. In clinical trials, cases occurred after 8 to 120 weeks of treatment. The FDA label notes that risk increases with longer treatment duration, particularly beyond two years. Patients who develop PML may experience rapid neurological decline, and early detection is crucial for any chance of improved outcomes. However, symptoms can be subtle initially, and delays in diagnosis are common. For patients and families affected by Tysabri-associated PML, consulting with a medical-legal professional may be appropriate to evaluate whether the warnings provided were adequate and whether the harm could have been prevented. Attorneys specializing in pharmaceutical injury can review medical records, assess risk factors, and determine if the manufacturer's communications met regulatory standards. The evidence underscores the importance of careful risk-benefit analysis before initiating Tysabri therapy and vigilant monitoring throughout treatment.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and why is it associated with PML?

Tysabri (natalizumab) is a biologic medication used to treat multiple sclerosis and Crohn's disease. It works by blocking immune cells from entering the brain, which can increase the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

The FDA label identifies three key risk factors: presence of anti-JCV antibodies, duration of therapy (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients with all three factors have the highest risk.

What are the symptoms of PML and how is it diagnosed?

Symptoms include progressive weakness, cognitive impairment, vision changes, and coordination problems. Diagnosis is confirmed by MRI and detection of JC virus DNA in cerebrospinal fluid. The FDA advises immediate discontinuation of Tysabri if PML is suspected (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Can I file a lawsuit if I developed PML from Tysabri?

If you or a loved one developed PML after Tysabri use, you may have legal grounds if the manufacturer failed to provide adequate warnings. An attorney can review your case to determine if the warnings were sufficient and if the harm could have been prevented. Contact a pharmaceutical injury lawyer for a consultation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.